Advertisement

World Journal of Surgery

, Volume 31, Issue 7, pp 1458–1468 | Cite as

Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery

  • Gennaro Galizia
  • Eva Lieto
  • Michele Orditura
  • Paolo Castellano
  • Anna La Mura
  • Vincenzo Imperatore
  • Margherita Pinto
  • Anna Zamboli
  • Ferdinando De Vita
  • Francesca Ferraraccio
Article

Abstract

Background

In gastric cancer, the recurrence rate is high even after curative surgery. A relevant issue is the identification of independent prognostic factors to select high-risk patients; such features can be used as predictive factors for tailored therapies. In this study we have investigated the role of epidermal growth factor receptor (EGFR) expression as a prognostic marker for predicting cancer behavior and clinical outcome in gastric cancer patients undergoing potentially curative surgery.

Methods

Epidermal growth factor receptor determination using a commercially available immunohistochemistry (IHC) kit was performed in tissues from 82 gastric cancer patients receiving primary surgical treatment and in 25 normal gastric mucosa specimens from noncancer patients. The EGFR positivity was correlated with disease recurrence and survival in univariate and multivariate analyses.

Results

Forty-four percent (36 cases) of gastric cancers were EGFR positive. In 66 curatively treated patients, EGFR expression correlated with disease recurrence and poorer survival in both univariate and multivariate analyses. In a multivariate model for predicting recurrence and survival, advanced tumor extension (T3 or T4), nodal metastases, and EGFR expression were the only independent covariates. In particular, EGFR expression was shown to be a significant predictor of poor prognosis among gastric cancer patients having the same stage according to the current TNM staging system.

Conclusions

These findings suggest that EGFR expression may be useful in identifying high-risk gastric cancer patients undergoing potentially curative surgery. Multimodal treatments should be considered in the adjuvant treatment of these patients.

Keywords

Gastric Cancer Epidermal Growth Factor Receptor Gastric Cancer Patient Epidermal Growth Factor Receptor Expression Epidermal Growth Factor Receptor Protein Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Jemal A, Siegel R, Ward E, et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRefGoogle Scholar
  2. 2.
    Hartgrink HH, van de Velde CJ (2005) Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer: J Surg Oncol 90:153–165PubMedCrossRefGoogle Scholar
  3. 3.
    Novotny AR, Schuhmaker C, Bush R, et al. (2006) Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 243:74–81PubMedCrossRefGoogle Scholar
  4. 4.
    Ajani JA, Mansfield PF, Crane CH, et al. (2005) Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23:1237–1244PubMedCrossRefGoogle Scholar
  5. 5.
    Allal AS, Zwahlen D, Brundler MA, et al. (2005) Neoadjuvant radiochemotherapy for locally advanced gastric cancer: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 63:1286–1289PubMedCrossRefGoogle Scholar
  6. 6.
    MacDonald JS (2005) Role of post-operative chemoradiation in resected gastric cancer. J Surg Oncol 90:166–170PubMedCrossRefGoogle Scholar
  7. 7.
    Kim S, Lim do H, Lee J, et al. (2005) An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 63:1279–285PubMedCrossRefGoogle Scholar
  8. 8.
    Allum W, Cunningham D, Weeden S, et al. (2003) Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomized, controlled trial (the MAGIC trial, ISRCTN 93793971) [Abstract #998], Proc ASCO 22:249aGoogle Scholar
  9. 9.
    Chong G, Cunningham D (2005) Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol 31:453–460PubMedCrossRefGoogle Scholar
  10. 10.
    Leong T (2004) Evolving role of chemoradiation in the adjuvant treatment of gastric cancer. Expert Rev Anticancer Ther 4:585–594PubMedCrossRefGoogle Scholar
  11. 11.
    Stahl M (2004) Adjuvant chemoradiotherapy in gastric cancer and carcinoma of the oesophago-gastric junction. Onkologie 27:33–36PubMedCrossRefGoogle Scholar
  12. 12.
    Hartgrink HH, van de Velde CJ, Putter H, et al. (2004) Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial. J Clin Oncol 22:2069–2077PubMedCrossRefGoogle Scholar
  13. 13.
    Hundahl SA, Wanebo HJ (2005) Changing gastric cancer treatment in the United States and the pursuit of quality. Eur J Surg Oncol 31:605–615PubMedCrossRefGoogle Scholar
  14. 14.
    Falcone A (2003) Future strategies and adjuvant treatment of gastric cancer. Ann Oncol 14:45–47CrossRefGoogle Scholar
  15. 15.
    Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98–107PubMedCrossRefGoogle Scholar
  16. 16.
    Wagner AD, Grothe W, Haerting J, et al. (2006) Chemotherapy in advanced gastric cancer: a systematic review and a meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909PubMedCrossRefGoogle Scholar
  17. 17.
    Sutter AP, Zeitz M, Scherübl H (2004) Recent results in understanding molecular pathways in the medical treatment of esophageal and gastric cancer. Onkologie 27:17–21PubMedCrossRefGoogle Scholar
  18. 18.
    Galizia G, Ferraraccio F, Lieto E, et al. (2006) p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. J Surg Oncol 93:241–252PubMedCrossRefGoogle Scholar
  19. 19.
    Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787–2799PubMedCrossRefGoogle Scholar
  20. 20.
    Garcia I, Vizoso F, Martin A, et al. (2003) Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10:234–241PubMedCrossRefGoogle Scholar
  21. 21.
    Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445–2459PubMedCrossRefGoogle Scholar
  22. 22.
    Grunwald V, Hidalgo M (2003) Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95:851–867PubMedCrossRefGoogle Scholar
  23. 23.
    Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958–2970PubMedGoogle Scholar
  24. 24.
    Galizia G, Lieto E, Ferrarraccio F, et al. (2006) Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 13:823–835PubMedCrossRefGoogle Scholar
  25. 25.
    Kopp R, Rothbauer E, Ruge M, et al. (2003) Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res 162:115–132PubMedGoogle Scholar
  26. 26.
    Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, et al. (2004) Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol 17:579–587PubMedCrossRefGoogle Scholar
  27. 27.
    Ito R, Nakayama H, Yoshida K, et al. (2004) Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma. Virchows Arch 444:324–331PubMedCrossRefGoogle Scholar
  28. 28.
    Grogg KL, Lohse CM, Pankratz VS, et al. (2003) Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol 16:641–651PubMedCrossRefGoogle Scholar
  29. 29.
    Hiyama T, Tanaka S, Yoshihara M, et al. (2004) Chromosomal and microsatellite instability in sporadic gastric cancer. J Gastroenterol Hepatol 19:756–760PubMedCrossRefGoogle Scholar
  30. 30.
    Kalbfleisch JD, Prentice RL (1980) The Statistical Analysis of Failure Time Data. New York, WileyGoogle Scholar
  31. 31.
    Santoro E, Carboni M, Catarci M, et al. (1997) DNA ploidy, proliferative index and EGF-R status in 130 cases of resected gastric cancer: a multivariate analysis. Hepatogastroenterology 44:826–837PubMedGoogle Scholar
  32. 32.
    Hirono Y, Tsugawa K, Fushida S, et al. (1995) Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology 52:182–188PubMedCrossRefGoogle Scholar
  33. 33.
    Sanz-Ortega J, Steinberg SM, Moro E, et al. (2000) Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol 15:455–462PubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2007

Authors and Affiliations

  • Gennaro Galizia
    • 1
  • Eva Lieto
    • 1
  • Michele Orditura
    • 2
  • Paolo Castellano
    • 1
  • Anna La Mura
    • 3
  • Vincenzo Imperatore
    • 1
  • Margherita Pinto
    • 1
  • Anna Zamboli
    • 1
  • Ferdinando De Vita
    • 2
  • Francesca Ferraraccio
    • 3
  1. 1.Division of Surgical Oncology, “F. Magrassi - A. Lanzara” Department of Clinical and Experimental Medicine and SurgerySecond University of Naples School of MedicineNaplesItaly
  2. 2.Division of Medical Oncology, “F. Magrassi - A. Lanzara” Department of Clinical and Experimental Medicine and SurgerySecond University of Naples School of MedicineNaplesItaly
  3. 3.Division of Pathology, “F. Magrassi - A. Lanzara” Department of Clinical and Experimental Medicine and SurgerySecond University of Naples School of MedicineNaplesItaly

Personalised recommendations